Evidence map›Paper›PMID 41531628›Full record

ArticleCureus2025

Sequential Folliculitis, Paraspinal Myositis, and Septic Arthritis Due to Hematogenous Staphylococcus aureus Infection in a Patient Receiving Adalimumab Therapy.

Ethan Burton, William Haller

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ethan BurtonOsteopathic Medicine, Edward Via College of Osteopathic Medicine, Auburn, USA.
William HallerOrthopedics, Gadsden Regional Medical Center, Gadsden, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin infections are a well-recognized source of bacteremia and can serve as foci for hematogenous spread leading to sepsis, septic arthritis, or osteomyelitis. Immunosuppressive therapies, particularly tumor necrosis factor alpha (TNF-α) inhibitors such as adalimumab, predispose patients to severe infections and are associated with increased infectious morbidity and mortality. These agents impair innate immune signaling and may attenuate the clinical manifestations of infection. Specifically, TNF-α blockade disrupts downstream interleukin-1β (IL-1β) and interleukin-6 (IL-6) pathways that mediate leukocyte recruitment and the febrile response. Consequently, patients receiving TNF-α inhibitors may present with bacteremia or early sepsis in the absence of typical findings such as fever or leukocytosis, potentially delaying diagnosis and treatment. We report a middle-aged Caucasian male patient receiving adalimumab therapy who initially presented to the emergency department with presumed paraspinal muscle strain and degenerative spondylosis. Magnetic resonance imaging (MRI) was interpreted as consistent with muscular strain and degenerative spondylosis. Subsequent orthopedic evaluation revealed a septic-appearing left knee, with synovial and blood cultures positive for methicillin-sensitive

Indexed as

adalimumabbacteremiahematogenous spreadparaspinal pyomyositisstaphylococcus aureustnf-alpha inhibitors

Identifiers

PMID41531628
PMCPMC12793604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.